|Bid||20.27 x 900|
|Ask||20.28 x 800|
|Day's Range||19.80 - 20.41|
|52 Week Range||13.42 - 25.31|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||9.78|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
You have to look hard to see value in today's pricey market, but here are three inexpensive stocks that should be on your radar today.
On CNBC's "Mad Money Lightning Round," Jim Cramer said Zebra Technologies Corp. (NASDAQ: ZBRA) is a fast-growing company and he is sticking by it because barcode technology is the way of the future. Cramer is not a buyer of EQM Midstream Partners LP (NYSE: EQM). Exelixis, Inc. (NASDAQ: EXEL) is a good spec, said Cramer.
Exelixis Inc NASDAQ/NGS:EXELView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for EXEL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.97 billion over the last one-month into ETFs that hold EXEL are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Exelixis, Inc. (NASDAQ:EXEL) from its intrinsic value? Using the most recent financial...
Exelixis (EXEL) delivered earnings and revenue surprises of 12.50% and 5.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Alameda, California-based company said it had net income of 24 cents. Earnings, adjusted for stock option expense, came to 27 cents per share. The results exceeded Wall Street ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...
This Peninsula drug developer has four preclinical drugs aimed at triggering a process that it believes will kill cancer cells with genetic mutations.
First-quarter earnings reports are flooding the wires this week and both the Nasdaq and S&P 500 have attained all-time highs. The space has been hurt by political rhetoric as the 2020 election cycle starts to get in full swing. Let's consider a few biotech names and start on a high note.
Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Exelixis, Inc. (NASDAQ:EXEL) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.